757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab

Kristoffer Staahl Rohrberg; Zsuzsanna Papai; Ana Carneiro; Istvan Lang; Jeffrey Yachnin; Sean Lim; Lars Ny; Rikke H Lovendahl Eefsen; Harriet Walter; Edvard Abel; Kirstie Cleary; Robert Oldham; Mark Cragg; Marie Borggren; Susanne Gertsson; Petra Holmkvist; Ingrid Karlsson; Linda Martensson; Jan Anders Nilsson; Johan E Wallin; Michael Chisamore; Bjorn Frendeus; Ingrid Teige; Andres McAllister

doi:10.1136/jitc-2023-SITC2023.0757

Citation Tools

Regular and Young Investigator Award Abstracts

Clinical Trial In Progress

757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Rohrberg KS, Papai Z, Carneiro A, et al

757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab

Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0757

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password